Barry Menna, DO
Neurology · Mount Kisco, NYNPI 1568442390
Payments from drug & device makers
Across 215 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$916
- Pfizer$217
- Teva Pharmaceuticals USA, Inc.$196
- Lilly USA, LLC$177
- Novartis$168
- EMD Serono, Inc.$141
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,22799%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 86 | $916 |
| Pfizer | 14 | $217 |
| Teva Pharmaceuticals USA, Inc. | 8 | $196 |
| Lilly USA, LLC | 12 | $177 |
| Novartis | 10 | $168 |
| EMD Serono, Inc. | 12 | $141 |
| UCB, Inc. | 8 | $140 |
| Biogen | 4 | $126 |
| MDD US Operations, LLC | 5 | $114 |
| Neurocrine Biosciences, Inc. | 6 | $107 |
| Livanova USA, Inc. | 2 | $91 |
| Acadia Pharmaceuticals Inc | 5 | $89 |
| Amneal Pharmaceuticals LLC | 4 | $74 |
| Medtronic | 1 | $70 |
| AstraZeneca | 5 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $65 |
| Genentech USA, Inc. | 3 | $58 |
| Eisai Inc. | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 4 | $44 |
| SK Life Science, Inc. | 2 | $43 |
| Amgen | 2 | $35 |
| Avanir Pharmaceuticals, Inc. | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Assertio Therapeutics, Inc. | 2 | $27 |
| Sanofi | 1 | $24 |
| Tanabe Pharma America, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $22 |
| Neurelis, Inc. | 1 | $21 |
| CSL Behring | 1 | $17 |
| Adamas Pharmaceuticals, Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
| Lundbeck LLC | 1 | $12 |
How this compares
$3,275 in reported general payments places this provider in the 60th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $172,546 |
| UbrelvyUbrogepant | 49 | $59,385 |
| Nurtec OdtRimegepant Sulfate | 41 | $43,327 |
| Emgality PenGalcanezumab-Gnlm | 41 | $37,324 |
| Emgality SyringeGalcanezumab-Gnlm | 15 | $16,966 |
| Aimovig AutoinjectorErenumab-Aooe | 21 | $14,865 |
| Memantine Hcl ErMemantine Hcl | 84 | $14,016 |
| Levetiracetam | 165 | $6,016 |
| Divalproex Sodium ErDivalproex Sodium | 24 | $4,707 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 69 | $2,622 |
| Ropinirole ErRopinirole Hcl | 14 | $1,852 |
| Donepezil Hcl | 117 | $1,728 |
| Propranolol Hcl | 58 | $1,633 |
| Selegiline Hcl | 14 | $1,474 |
| Pregabalin | 27 | $1,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $107 | $172,54620 claims |
| AbbVieUbrelvy | $916 | $59,38549 claims |
| PfizerNurtec Odt | $217 | $43,32741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,623 neurology providers in New York.
Other neurology in Mount Kisco
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
- Krupa PandeyAlbany$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.